Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 4/20 | 0.34 |
| ▸ | PPARA | Q07869 | 5/20 | 0.33 |
| ▸ | PPARD | Q03181 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917854 | 0.88 | PTGDR2 (0.36) | FFAR4PTGDR2SSTR5PPARA | |
| SCHEMBL3674939 | 0.79 | PTGDR2 (0.35) | PTGDR2SSTR5PPARAPPARD | |
| SCHEMBL3674756 | 0.76 | SSTR5 (0.35) | PTGDR2SSTR5 | |
| SCHEMBL917561 | 0.76 | PPARA (0.33) | CYP2C9SSTR5PPARAPPARG | |
| SCHEMBL4867660 | 0.76 | PDE4B (0.42) | SSTR5 | |
| SCHEMBL3679579 | 0.75 | SSTR5 (0.34) | SSTR5 | |
| SCHEMBL917121 | 0.75 | FPR2 (0.34) | SSTR5 | |
| SCHEMBL3671921 | 0.75 | SSTR5 (0.39) | SSTR5 | |
| SCHEMBL3549573 | 0.75 | PDE4B (0.39) | — | |
| SCHEMBL3679430 | 0.75 | SSTR5 (0.39) | SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | FFAR4 584/4885FFAR1 877/4885PTGDR2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.